Drug discovery from Chinese medicine against neurodegeneration in Alzheimer's and vascular dementia

Yuen-Shan Ho, Kwok-Fai So, Raymond Chuen-Chung Chang, Yuen-Shan Ho, Kwok-Fai So, Raymond Chuen-Chung Chang

Abstract

Alzheimer's disease and vascular dementia are two major diseases associated with dementia, which is common among the elderly. While the etiology of dementia is multi-factorial and complex, neurodegeneration may be the major cause of these two diseases. Effective drugs for treating dementia are still to be discovered. Current western pharmacological approaches against neurodegeneration in dementia develop symptom-relieving and disease-modifying drugs. Current integrative and holistic approaches of Chinese medicine to discovering drugs for neurodegeneration in dementia include (1) single molecules from the herbs, (2) standardized extracts from a single herb, and (3) herbal formula with definite composition. This article not only reviews the concept of dementia in western medicine and Chinese medicine but also evaluates the advantages and disadvantages of these approaches.

References

    1. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement. 2010;6:158–194.
    1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112–2117.
    1. Song Y, Wang J. Overview of Chinese research on senile dementia in mainland China. Ageing Res Rev. 2010. pp. S6–12.
    1. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362:329–344. doi: 10.1056/NEJMra0909142.
    1. Iqbal K, Grundke-Iqbal I. Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med. 2008;12:38–55.
    1. Mayeux R. Clinical practice. Early Alzheimer's disease. N Engl J Med. 2010;362:2194–2201. doi: 10.1056/NEJMcp0910236.
    1. Gorelick PB. Risk factors for vascular dementia and Alzheimer disease. Stroke. 2004;35(Suppl 1):2620–2622.
    1. Lindsay J, Hebert R, Rockwood K. The Canadian study of health and aging: risk factors for vascular dementia. Stroke. 1997;28:526–530.
    1. Ho YS, So KF, Chang RCC. Anti-aging herbal medicine--how and why can they be used in aging-associated neurodegenerative diseases? Ageing Res Rev. 2010;9:354–362. doi: 10.1016/j.arr.2009.10.001.
    1. Fu RJ. Guidelines for TCM diagnosis, classification and clinical research of senile dementia. J Tradit Chin Med. 1991;2:56–57.
    1. Fu RJ, Luo SW. Review on clinical research of senile dementia treated by TCM. J Beijing University of TCM. 1994;3:146–152.
    1. Tian JZ, Ming XH, Jin WT. Criteria for the diagnosis, the differentiation of syndrome and the evaluation of efficacy of vascular dementia for research studies. Chin J Gerontol. 2002;5:329–331.
    1. Tian JZ, Han XM, Yue JM, Yang CZ, Yang HM, Zou YH, Liu X. The scale for the differentiation of syndromes of vascular dementia (SDSVD) J Beijing University TCM. 2000;23:16–24.
    1. Dong HT, Jin YG. A discussion on the etiology and pathogenesis of senile dementia due to stagnation of blood-stasis in the orifice. Nanjing University of TCM. 2003;35:3–4.
    1. Zhang G, Wang FW. Recent progress in Chinese medicine clinical research on vascular dementia. Lishizhen Med Mater Med Res. 2010;3:769–771.
    1. Yuen DP, Qiu XF, Wang P, Zhou AF. Deficiency of kidney and febility of marrow, blockage of brain vollateral: basic pathogenesis of Alzheimer's disease (AD) Zhonghua Zhongyiyao Zazhi. 2008;8:732–734.
    1. Wang XY, Liu CP, Chen YW. Recent progress in TCM research on Alzheimer's disease pathogenesis. Neimengguz Zhong Yi Yao. 2008;12:62–64.
    1. Yang BC, Liu RR, Xue RH, Ye SL. Research on TCM pattern identification in dementia of the Alzheimer type. Shanghai J Tradit Chin Med. 2000;4:12–14.
    1. Wang BS, Wang H, Wei ZH, Song YY, Zhang L, Chen HZ. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis. J Neural Transm. 2009;116:457–465. doi: 10.1007/s00702-009-0189-x.
    1. Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin. 2006;27:1–26. doi: 10.1111/j.1745-7254.2006.00255.x.
    1. Li J, Wu HM, Zhou RL, Liu GJ, Dong BR. Huperzine A for Alzheimer's disease. Cochrane Database Syst Rev. 2008. p. CD005592.
    1. Ma X, Tan C, Zhu D, Gang DR, Xiao P. Huperzine A from Huperzia species--an ethnopharmacolgical review. J Ethnopharmacol. 2007;113:15–34. doi: 10.1016/j.jep.2007.05.030.
    1. Liang YQ, Tang XC. Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats. Acta Pharmacol Sin. 2006;27:1127–1136. doi: 10.1111/j.1745-7254.2006.00411.x.
    1. Zhang HY, Yan H, Tang XC. Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-alpha in intracerebroventricular beta-amyloid-(1-40) infused rats and human embryonic kidney 293 Swedish mutant cells. Neurosci Lett. 2004;360:21–24. doi: 10.1016/j.neulet.2004.01.055.
    1. Xiao XQ, Zhang HY, Tang XC. Huperzine A attenuates amyloid beta-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J Neurosci Res. 2002;67:30–36. doi: 10.1002/jnr.10075.
    1. Wang R, Xiao XQ, Tang XC. Huperzine A attenuates hydrogen peroxide-induced apoptosis by regulating expression of apoptosis-related genes in rat PC12 cells. Neuroreport. 2001;12:2629–2634. doi: 10.1097/00001756-200108280-00009.
    1. Xiao XQ, Wang R, Tang XC. Huperzine A and tacrine attenuate beta-amyloid peptide-induced oxidative injury. J Neurosci Res. 2000;61:564–569. doi: 10.1002/1097-4547(20000901)61:5<564::AID-JNR11>;2-X.
    1. Gao X, Tang XC. Huperzine A attenuates mitochondrial dysfunction in beta-amyloid-treated PC12 cells by reducing oxygen free radicals accumulation and improving mitochondrial energy metabolism. J Neurosci Res. 2006;83:1048–1057. doi: 10.1002/jnr.20791.
    1. Pan SY, Chen SB, Dong HG, Yu ZL, Dong JC, Long ZX, Fong WF, Han YF, Ko KM. New perspectives on Chinese herbal medicine (Zhong-Yao) research and development. Evid Based Complement Alternat Med. 2010;2011:403709.
    1. Wang Y, Huang LQ, Tang XC, Zhang HY. Retrospect and prospect of active principles from Chinese herbs in the treatment of dementia. Acta Pharmacol Sin. 2010;31:649–664. doi: 10.1038/aps.2010.46.
    1. Anekonda TS, Reddy PH. Can herbs provide a new generation of drugs for treating Alzheimer's disease? Brain Res Rev. 2005;50:361–376. doi: 10.1016/j.brainresrev.2005.09.001.
    1. Luo Q, Cai Y, Yan J, Sun M, Corke H. Hypoglycemic and hypolipidemic effects and antioxidant activity of fruit extracts from Lycium barbarum. Life Sci. 2004;76:137–149. doi: 10.1016/j.lfs.2004.04.056.
    1. Normile D. Asian medicine. The new face of traditional Chinese medicine. Science. 2003;299:188–190. doi: 10.1126/science.299.5604.188.
    1. Leung PC, Cheng KF. Good agricultural practice (GAP) -Does it ensure a perfect supply of medicinal herbs for research and drug development? Int J Appl Res Nat Prod. 2008;1:1–8.
    1. Zhang B, Peng Y, Zhang Z, Liu H, Qi Y, Liu S, Xiao P. GAP production of TCM herbs in China. Planta Med. 2010;76:1948–1955. doi: 10.1055/s-0030-1250527.
    1. Clostre F. Ginkgo biloba extract (EGb 761). State of knowledge in the dawn of the year 2000. Ann Pharm Fr. 1999;57(Suppl 1):1S8–88.
    1. Chen WD, Liang Y, Xie L, Lu T, Liu XD, Wang GJ. Pharmacokinetics of the ginkgo B following intravenous administration of ginkgo B emulsion in rats. Biol Pharm Bull. 2007;30:1–5. doi: 10.1248/bpb.30.1.
    1. Lee TF, Chen CF, Wang LC. Effect of ginkgolides on beta-amyloid-suppressed acetylocholine release from rat hippocampal slices. Phytother Res. 2004;18:556–560. doi: 10.1002/ptr.1493.
    1. Zhou LJ, Zhu XZ. Reactive oxygen species-induced apoptosis in PC12 cells and protective effect of bilobalide. J Pharmacol Exp Ther. 2000;293:982–988.
    1. Birks J, Grimley EJ. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2009. p. CD003120.
    1. Dekosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300:2253–2262. doi: 10.1001/jama.2008.683.
    1. Chang RCC, So KF. Use of Anti-aging Herbal Medicine, Lycium barbarum, Against Aging-associated Diseases. What Do We Know So Far? Cell Mol Neurobiol. 2007;28:643–652.
    1. Yu MS, Leung SK, Lai SW, Che CM, Zee SY, So KF, Yuen WH, Chang RCC. Neuroprotective effects of anti-aging oriental medicine Lycium barbarum against beta-amyloid peptide neurotoxicity. Exp Gerontol. 2005;40:716–727. doi: 10.1016/j.exger.2005.06.010.
    1. Ho YS, Yu MS, Yik SY, So KF, Yuen WH, Chang RCC. Polysaccharides from wolfberry antagonizes glutamate excitotoxicity in rat cortical neurons. Cell Mol Neurobiol. 2009;29:1233–1244. doi: 10.1007/s10571-009-9419-x.
    1. Ho YS, Yu MS, Yang XF, So KF, Yuen WH, Chang RCC. Neuroprotective effects of polysaccharides from wolfberry, the fruits of Lycium barbarum, against homocysteine-induced toxicity in rat cortical neurons. J Alzheimers Dis. 2010;19:813–827.
    1. Mizoguchi K, Tanaka Y, Tabira T. Anxiolytic effect of a herbal medicine, yokukansan, in aged rats: Involvement of serotonergic and dopaminergic transmissions in the prefrontal cortex. J Ethnopharmacol. 2010;127:70–76. doi: 10.1016/j.jep.2009.09.048.
    1. Iwasaki K, Satoh-Nakagawa T, Maruyama M, Monma Y, Nemoto M, Tomita N, Tanji H, Fujiwara H, Seki T, Fujii M, Arai H, Sasaki H. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry. 2005;66:248–252. doi: 10.4088/JCP.v66n0214.
    1. Lawlor BA. Behavioral and psychological symptoms in dementia: the role of atypical antipsychotics. J Clin Psychiatry. 2004;65(Suppl 11):5–10.
    1. Iwasaki K, Maruyama M, Tomita N, Furukawa K, Nemoto M, Fujiwara H, Seki T, Fujii M, Kodama M, Arai H. Effects of the traditional Chinese herbal medicine Yi-Gan San for cholinesterase inhibitor-resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies. J Clin Psychiatry. 2005;66:1612–1613. doi: 10.4088/JCP.v66n1219a.
    1. Shinno H, Inami Y, Inagaki T, Nakamura Y, Horiguchi J. Effect of Yi-Gan San on psychiatric symptoms and sleep structure at patients with behavioral and psychological symptoms of dementia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:881–885. doi: 10.1016/j.pnpbp.2007.12.027.
    1. Mizukami K, Asada T, Kinoshita T, Tanaka K, Sonohara K, Nakai R, Yamaguchi K, Hanyu H, Kanaya K, Takao T, Okada M, Kudo S, Kotoku H, Iwakiri M, Kurita H, Miyamura T, Kawasaki Y, Omori K, Shiozaki K, Odawara T, Suzuki T, Yamada S, Nakamura Y, Toba K. A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia. Int J Neuropsychopharmacol. 2009;12:191–199. doi: 10.1017/S146114570800970X.
    1. Kawanabe T, Yoritaka A, Shimura H, Oizumi H, Tanaka S, Hattori N. Successful treatment with Yokukansan for behavioral and psychological symptoms of Parkinsonian dementia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:284–287. doi: 10.1016/j.pnpbp.2009.11.019.
    1. Okahara K, Ishida Y, Hayashi Y, Inoue T, Tsuruta K, Takeuchi K, Yoshimuta H, Kiue K, Ninomiya Y, Kawano J, Yoshida K, Noda S, Tomita S, Fujimoto M, Hosomi J, Mitsuyama Y. Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:532–536. doi: 10.1016/j.pnpbp.2010.02.013.
    1. Takeda A, Itoh H, Tamano H, Yuzurihara M, Oku N. Suppressive effect of Yokukansan on excessive release of glutamate and aspartate in the hippocampus of zinc-deficient rats. Nutr Neurosci. 2008;11:41–46. doi: 10.1179/147683008X301414.
    1. Takeda A, Tamano H, Itoh H, Oku N. Attenuation of abnormal glutamate release in zinc deficiency by zinc and Yokukansan. Neurochem Int. 2008;53:230–235. doi: 10.1016/j.neuint.2008.07.009.
    1. Kawakami Z, Kanno H, Ueki T, Terawaki K, Tabuchi M, Ikarashi Y, Kase Y. Neuroprotective effects of yokukansan, a traditional Japanese medicine, on glutamate-mediated excitotoxicity in cultured cells. Neuroscience. 2009;159:1397–1407. doi: 10.1016/j.neuroscience.2009.02.004.
    1. Egashira N, Iwasaki K, Ishibashi A, Hayakawa K, Okuno R, Abe M, Uchida N, Mishima K, Takasaki K, Nishimura R, Oishi R, Fujiwara M. Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1516–1520. doi: 10.1016/j.pnpbp.2008.05.010.
    1. Zhu AH, Tian JZ, Zhong J, Yang CZ, Shi J, Yin JX. A clinical study on a randomized, double-blind control of Chinese medicine granules in treatment of vascular dementia. Zhongguo Zhong Yao Za Zhi. 2006;31:1722–1725.
    1. Du GY, Zhu XC, Zhao JJ, Wang J, Tian JZ, Liu XF, Zhi HP, Zhao Y, Cao CY, Cui HF, Wang XR, Zhang CY. Clinical study of effect of tianzhi granule on senile vascular dementia. Zhongguo Zhong Yao Za Zhi. 2003;28:73–77.
    1. Lam CLK, Wong W, Fong DY. Chinese herbal medicine in the treatment of acute upper respiratory tract infection: a randomised, double blind, placebo-controlled clinical trial. Hong Kong Med J. 2009;15(Suppl 6):30–34.
    1. Liu W, Zhang GL, Wang XL. Application and prospects of fan-sui relation in TCM in preventing and treating encephalopathy. Zonghua Zhongyiyao Za Zhi. 2010;25:993–996.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir